Table 1.

Pharmacokinetic Parameters in Patients With Systemic Lupus Erythematosus After Intravenous Belimumab 10 mg/kg^*

Parameter	Population Estimate (N = 563)
Peak concentration (Cmax, mcg/mL)	313
Area under the curve (AUC0-∞, day • mcg/mL)	3,083
Distribution half-life (days)	1.75
Terminal half-life (days)	19.4
Systemic clearance (mL/day)	215
Volume of distribution (L)	5.29

^*Intravenous infusions were administered at 2-week intervals for the first three doses and at 4-week intervals thereafter. (From Benlysta prescribing information.¹²)